Sept 6 (Reuters) - Immutep Ltd (IMM) :
- IMMUTEP ANNOUNCES INVESTIGATOR-INITIATED PHASE II TRIAL EVALUATING LAG-3 CANDIDATE EFTILAGIMOD ALPHA (EFTI) IN SOFT TISSUE SARCOMA
- IMMUTEP LTD - FIRST PATIENT DOSE ANTICIPATED BY H1 2023
- IMMUTEP LTD - DOSING OF FIRST PATIENT IS ANTICIPATED IN FIRST HALF OF CALENDAR YEAR 2023, WITH INITIAL INTERIM DATA EXPECTED IN Q4 OF CY 2024
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
25.0¢ |
Change
-0.010(3.85%) |
Mkt cap ! $366.9M | |||
| Open | High | Low | Value | Volume |
| 26.0¢ | 26.0¢ | 24.8¢ | $362.9K | 1.448M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 42000 | 25.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 25.5¢ | 271046 | 5 |
View Market Depth
| Last trade - 16.10pm 16/09/2025 (20 minute delay) ? |
| IMM (ASX) Chart |